Search research articles
Contact Us
Filters
Showing results (11-20 of 14) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 14 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 17, 2012
Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia
T Steinmetz, B Tschechne, O Harlin, et al.
Cancer Treatment Reviews
|
November 7, 2006
Bisphosphonate-related jaw necrosis--severe complication in maxillofacial surgery
A W Eckert, P Maurer, L Meyer, et al.
Zeitschrift Fur Die Gesamte Innere Medizin Und Ihre Grenzgebiete
|
October 1, 1986
[Clinical aspects and prognosis of highly malignant non-Hodgkin's lymphomas]
R Rohrberg, K Krug, D Krahl, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 30, 2017
Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study
B Schultheis, D Reuter, M P Ebert, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 14) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 14 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 17, 2012
Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia
T Steinmetz, B Tschechne, O Harlin, et al.
Cancer Treatment Reviews
|
November 7, 2006
Bisphosphonate-related jaw necrosis--severe complication in maxillofacial surgery
A W Eckert, P Maurer, L Meyer, et al.
Zeitschrift Fur Die Gesamte Innere Medizin Und Ihre Grenzgebiete
|
October 1, 1986
[Clinical aspects and prognosis of highly malignant non-Hodgkin's lymphomas]
R Rohrberg, K Krug, D Krahl, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 30, 2017
Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study
B Schultheis, D Reuter, M P Ebert, et al.
Page
of 2